The U.S. Food and Drug Administration has granted Fast Track designation to AntiBKV, Memo Therapeutics’ lead antibody that targets B.K. polyomavirus infection commonly seen in renal transplant patients. AntiBKV has completed a phase I clinical study and, following FDA clearance, has started actively recruiting patients for a pivotal phase II/III clinical trial. The drug is scheduled to be launched in 2025.
